Zhang, Wenyong W <br/><br/>
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Aug 2009 
 - 3642-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2008.19.4076  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Analysis of Variance<br/>Benzamides<br/>Blast Crisis--genetics<br/>Cohort Studies<br/>DNA Mutational Analysis<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Follow-Up Studies<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Genes, abl<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Mutation--drug effects<br/>Pharmacogenetics<br/>Piperazines--administration & dosage<br/>Probability<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Retrospective Studies<br/>Risk Assessment<br/>Severity of Illness Index<br/>Survival Analysis<br/>Treatment Outcome